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ABSTRACT 1 
Introduction: Persistent smoking in patients diagnosed with coronary heart disease 2 (CHD) has a significant effect on morbidity and mortality. Although there has been 3 considerable debate around gender differences in smoking cessation, conclusive 4 evidence on how gender impacts rates of smoking cessation and/or relapse following 5 CHD diagnosis is lacking.  6 
Aims and Methods: Our aim was to test the hypothesis that female smokers with CHD 7 are more likely to persist in smoking or relapse post-diagnosis or hospitalisation than 8 male smokers. We searched PubMed and Web of Science databases for studies 9 published in the last ten years. Meta-analyses were conducted using a random effects 10 model.  11 
Results: Sixteen studies met the inclusion criteria. The aggregated sample size was 12 36591, 20617 (56%) were smokers of which 2564 (12%) were females. Meta-analysis 13 of eight studies where smoking prevalence could be measured showed that females 14 were less likely to be smokers at baseline than males (OR 0.30, 95% CI 0.13 to 0.70). 15 Overall, one in two (47%) smokers persisted in smoking/relapsed following a diagnosis 16 or hospitalisation for CHD but there was no gender difference in the rate of persistent 17 smoking/relapse (OR 1.07, 95% CI 0.95 to 1.21). 18 
Conclusions: Female smokers with CHD were relatively uncommon in the included 19 study populations. However, the rate of persistent smoking/relapse was high in both 20 female and male smokers following a diagnosis or hospitalisation for CHD. Therefore 21 similar, sustained smoking cessation efforts are warranted for both genders. 22 
Keywords: Smoking, smoking relapse, smoking cessation, gender, cardiovascular 23 disease  24 
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INTRODUCTION 1 Coronary heart disease (CHD) is the leading cause of death worldwide and smoking is 2 one of the main modifiable risk factors. CHD includes acute coronary syndrome (ACS), 3 which incorporates myocardial infarction (MI) and unstable angina, as well as chronic 4 conditions such as stable angina and chronic ischemic heart disease. Within five years of 5 first MI more than one in three people die, more one in five have a recurrent event, and 6 more than one in ten develop heart failure.1 In 2013, CHD accounted for over 8 million 7 deaths worldwide, and was the largest single cause of death.2  8 The association between smoking and CHD - as well as cancer and other diseases 9 - is well established; it is estimated that globally 12% of CHD deaths are attributable to 10 tobacco, and in the USA tobacco smoking and exposure to second hand smoke are 11 responsible for almost one third of CHD deaths.1,3 Smoking has been identified as one of 12 the most important modifiable risk factors for cardiovascular morbidity and mortality 13 and is consistently used in the assessment of cardiovascular risk.4,5 There is concern 14 that the disease risk associated with smoking may be even greater for females than for 15 males.6 Data from the United Kingdom showed that the relative risk of death from CHD 16 in females who smoked was more than four times that of females who had never 17 smoked.7 Furthermore, a recent systematic review and meta-analysis found that 18 females who smoke have a 25% greater relative risk of CHD than male smokers.8 19 Although smoking cessation is a well-established public health priority, and rates of 20 smoking are in decline in developed countries, smoking amongst females worldwide has 21 been predicted to double between 2005 and 2025 due to the growing prevalence of 22 smoking in developing countries and tobacco use continues to be the leading global 23 cause of preventable death.1,9,10  24 
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 Whilst life-saving secondary prevention interventions exist for people diagnosed 1 with CHD, the benefits achieved from these treatments is lower in patients who smoke. 2 Smoking cessation in patients diagnosed with CHD significantly reduces further cardiac 3 morbidity and mortality.11 Conversely, continued smoking has been associated with 4 progression of CHD and re-stenosis following coronary interventions.12 In spite of this, 5 many CHD patients persist in smoking or relapse post-discharge from hospital.5 6 Smoking cessation and relapse are recognised in the literature as a complex set of 7 behaviours, influenced by socio-economic factors, depression and anxiety, physical and 8 psychological dependence, weight gain concerns and home/work environment as well 9 as physiological attributes.13-16  10 Literature on tobacco use and smoking cessation interventions suggests that 11 differences exist between females and males who smoke.  For example, research has 12 considered the role of sex hormones and the menstrual cycle in relation to gender 13 differences in smoking behaviour.15,17 Consequently, there has been some speculation 14 and debate regarding whether females have more difficulty in quitting smoking than 15 males or are more vulnerable to relapse.16-20 Gender differences in the experience of 16 smoking cessation and relapse in patients with CHD have implications for the design 17 and implementation of smoking cessation interventions.8,15,17 To date there has been no 18 published systematic review focusing on gender differences in relapse in the CHD 19 population. Therefore, this study aims to test the hypothesis that female smokers are 20 more likely to persist in smoking or relapse than males following a diagnosis or 21 hospitalisation for CHD.  22 
 23   24 
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METHODS 1 
Literature search strategy 2 We conducted a systematic review following the Preferred Reporting Items for 3 Systematic Reviews and Meta-Analyses (PRISMA) guideline for systematic reviews and 4 meta-analysis.21 Pre-determined search criteria were used to extract relevant studies 5 published in peer reviewed, scientific literature.  PubMed and Web of Science databases 6 were searched for studies published in last ten years, and the final search was 7 conducted on February 16th 2015, with no further limitations. We restricted our search 8 to ten year limit, because smoking prevalence and policies have changed due to 9 progressive global implementation of the World Health Organisation Framework 10 Convention on Tobacco Control. Our intention to conduct this systematic review was to 11 test our hypothesis within a recent period, to get an indication whether further research 12 is required or not on this issue. We used the following search terms: (Ischemic heart 13 disease* OR Ischaemic heart disease* OR Cardiovascular disease* OR Cardiovascular 14 risk* OR Myocardial ischemia* OR Myocardial ischaemia* OR Acute Coronary 15 Syndrome* OR Angina pectoris OR Unstable angina* OR Microvascular angina* OR 16 Coronary disease* OR Coronary heart disease* OR Coronary aneurysm* OR Coronary 17 artery disease* OR Coronary occlusion* OR Coronary stenosis* OR Coronary thrombos* 18 OR Coronary vasospasm* OR Myocardial infarct* OR Myocardial stunning* OR 19 Cardiogenic shock* OR Myocardial reperfusion injur* OR Heart disease*) AND (Woman 20 OR Women OR Gender OR Sex OR Female*) AND (Smoking cessation OR Quit smoking 21 OR Quit tobacco OR Smoking intervention* OR Smoking cessation relapse*).  22 
Inclusion criteria  23 The aim was to identify studies reporting smoking cessation and/or persistent smoking 24 or relapse amongst CHD patients by gender. The initial search revealed 3599 articles 25   5 | P a g e   
from which 274 were removed as duplicates. Firstly, articles were screened for 1 relevance by two reviewers based on titles and abstracts, and articles not relevant to 2 the hypothesis were excluded. Remaining studies were reviewed in detail by two 3 separate researchers to determine whether they related to CHD populations and 4 included results (raw data or odds ratios and confidence intervals) of smoking cessation 5 and/or persistence/relapse by gender.  Areas of uncertainty or disagreement between 6 the two researchers were resolved by discussion. Detailed search results are presented 7 in Figure 1. 8  In total, 16 studies were selected which inform the current understanding of 9 persistent smoking or relapse amongst females compared to males following a 10 diagnosis or hospitalisation for CHD.22-37 A data extraction spread sheet was used to 11 extract the following information: study description: author, study year, study design 12 and population description, and (by gender) the total sample size, number of smokers at 13 baseline, number of ceased smokers, number of persistent/relapsed smokers, odds 14 ratio and 95% confidence interval (CI) for persistence/relapse by gender if available, 15 definition of relapse and length of follow-up period.  16 
Statistical analyses  17 Statistical analyses were performed using MedCalc for Windows Version 13.3.3 18 (MedCalc software, Ostend, Belgium). Odds ratios and 95% CIs for female to male 19 smoking prevalence and female to male smoking persistence/relapse were calculated or 20 extracted from the article. Meta-analyses were carried out using the Comprehensive 21 Meta-Analysis package, version 2 (Biostat, Englewood, NJ, USA.) and the results for 22 smoking persistence/relapse are summarised in chronological order of publication in a 23 forest plot. The more conservative random effects model was utilised rather than the 24 fixed effects approach, as differences between the included studies precluded the 25   6 | P a g e   
assumption of a common effect size. Sensitivity analyses were performed by 1 recalculating the overall odds ratio with each study removed from the overall sample to 2 determine the impact of studies with large numbers and by sub-group (upper age limit 3 of the study population, baseline diagnosis type of the study population, baseline 4 coronary interventions of the study population, baseline smoking prevalence, definition 5 of persistent smoking/relapse, and length of follow-up).  6 
 7 
Critical appraisal 8 Quality of the selected studies was assessed using the Cochrane Grading of 9 Recommendations Assessment, Development and Evaluation (GRADE) approach.38 10 
 11 
RESULTS 12 Characteristics of the 16 included studies have been summarised in Table 1. On 13 aggregate, the sample size was 36591, 20617 (56%) were smokers of which 2564 14 (12%) were female. The average age range of the study population of the selected 15 studies was 51-64 years. The profile of each study population in terms of gender and 16 smoking status at baseline is presented in Figure 2, demonstrating that the majority of 17 CHD patients were male and that female smokers were a minority. Half of the included 18 studies only recruited patients who were smokers at baseline, 22,25,26,28,31,33,36,37 19 therefore, the prevalence of smoking at baseline in the aggregated sample is likely to be 20 larger than in the general CHD population. Study populations were homogenous as they 21 had all been diagnosed or hospitalised with CHD. Four studies were limited to 22 MI26,28,29,34; three studies included only patients who had received a coronary 23 intervention (PCI with stent and/or coronary artery bypass grafting (CABG) and/or 24 
  7 | P a g e   
valve surgery)23,24,32, whereas others included CHD patients with or without 1 intervention. Four studies had an upper age limit, meaning that elderly patients were 2 excluded from the sample.32,34,35,37 Two studies were based on data from the multi-3 country European Action on Secondary Prevention through Intervention to Reduce 4 Events (EUROASPIRE) survey, but there was no overlap in the study populations since 5 these articles were from separate waves of the survey.35,37 In most cases, study 6 populations were recruited from hospitals or patient databases, with one exception 7 which included a population sample.30  8 
Smoking prevalence at baseline 9 Amongst the eight studies which recruited both smokers and non-smokers with 10 CHD,23,24,27,29,30,32,34,35 the average smoking prevalence at baseline was 51% (SD ±15). 11 Prevalence of smoking at baseline by gender is shown in Table 2. Females with CHD 12 were significantly less likely to be smokers than males in six of the eight studies. The 13 average rate of smoking at baseline in females was 31% (SD ±14) compared to 57% (SD 14 ±18) in males (p<0.0001). Subsequently, meta-analysis of all eight studies revealed that 15 females had a 70% lower odds of being smokers at baseline than males (OR 0.30, 95% 16 CI 0.13 to 0.70). The direction of effect did not differ when sensitivity analyses were 17 conducted excluding each study in turn or by subgroup analyses (data analyses not 18 shown). 19 
Persistent smoking/relapse 20 Rates of persistent smoking/relapse by gender are presented (Table 2) and ranged 21 from 7%-63%, with smoking relapse being lowest in the study limited to patients 22 interviewed 90 days following CABG.32 On average, across 14 studies which provided 23 the number of persistent/relapsed smokers as opposed to odds ratios and CIs, almost 24 one in two (47% SD ±16) smokers was still smoking at follow-up. Persistent 25   8 | P a g e   
smoking/relapse was significantly higher in females in two studies,23,25 but was similar 1 between genders in all other studies. There was no gender difference in the rate of 2 persistent smoking/relapse in the meta-analysis of all sixteen included studies (OR 1.07, 3 95% CI 0.95 to 1.21) and this result was consistent when sensitivity analyses were 4 conducted excluding each study in turn and also when we considered the overall odds 5 ratio in the fixed effects model (Figure 3). 6  Smoking status at follow-up was invariably based on patients’ self-reporting, but 7 follow-up periods within which persistent smoking behaviour or relapse was assessed 8 varied considerably between studies (Table 1). Length of follow-up was summarised 9 into five categories which showed that: three studies followed patients up to 3 10 months29,31,32; two up to six months22,26; four up to 12 months25,27,33,36; six followed 11 patients for 1-3 years23,24,30,34,35,37; and, one study followed patients for up to 13 years.28 12 Relapse rates were lower in the studies which followed-up only until 3 months and 13 higher in studies which followed-up until 12 months, but length of follow-up did not 14 affect the direction of effect when sensitivity analyses were conducted. The rate of 15 relapse was similar in males and females even when the results were analysed by sub-16 group classified on length of follow-up category. 17 
Quality level of the selected studies 18 Grading was undertaken independently by two authors. The GRADE approach was 19 designed to be used in evaluating clinical trials/interventions being systematically 20 reviewed and, therefore, observational studies have a default rating of “low.”38 Although 21 upgrading and downgrading of studies can occur in some circumstances, all of the 22 observational studies in this current review remained in the low quality category.39 The 23 two randomized controlled trials included in the review were also rated “low”, because 24 
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they did not provide the number of persistent/ relapsed smokers by gender; they 1 provided odds ratios which we were able to include in the meta-analysis. 2  3 
DISCUSSION 4 The key finding of this systematic review and meta-analyses was that, although female 5 smokers formed only a small minority of the CHD population, those still smoking at the 6 time of diagnosis or hospitalisation were just as likely as male smokers to persist in 7 smoking or relapse following hospital discharge.  8  The finding that just over half of the aggregated study population were smokers, 9 whilst considerably higher than smoking prevalence in the general population where 10 each of the studies originated,9 is comparable to other studies of patients with CHD. 11 Although the number of smokers worldwide continues to increase due to population 12 growth, the prevalence of smoking has declined over the last twenty-five years so that 13 6% of females and 31% of males worldwide are currently estimated to smoke.40 14 However, population smoking prevalence varies considerably around the world from 15 <5% to >40% in some countries.9 Smoking prevalence also varies by age group, tending 16 to be higher amongst young people and decline with age; for example in Australia 8% of 17 females and 12% of males in the 65-74 age group smoke, compared with national 18 averages of 14% and 18% respectively.41 Despite this pattern, amongst people 19 diagnosed or hospitalised for CHD – who are typically aged over 50 - smoking 20 prevalence tends to be higher because of the role of smoking in the development of 21 atherosclerosis leading to CHD.42-44  22 In our study we found a gender difference in the prevalence of smoking, whereby 23 females with CHD were significantly less likely than males to be smokers at the time of 24 diagnosis or hospitalisation, which is consistent with patterns of smoking prevalence by 25   10 | P a g e   
gender in the global population as well as those found in many other CHD studies.40,41,45-1 
47 There is a possibility that, because female smokers form such a minority of the CHD 2 population, delivery of smoking cessation advice and intervention for females could be 3 overlooked. This is a concern because, as foreshadowed, the risks from smoking are 4 even greater for females than males and the dangers of relapse post-diagnosis or 5 hospitalisation for CHD are significant in terms of subsequent mortality and morbidity 6 in both genders.8,19,25,36,42 7  In this meta-analysis, the rate of persistent smoking or relapse post-diagnosis or 8 hospitalisation was similar amongst females and males. This is contrary to our 9 hypothesis which suggested that females might find it more difficult to quit smoking 10 than males and, therefore, be more vulnerable to relapse. However, a non-significant 11 relationship between relapse and gender has been noted in several other CHD 12 studies.14,47-51 Recent population cohort studies and meta-analyses of non-CHD 13 populations have also found that females were neither less likely to quit smoking nor 14 less successful in their quit attempts than males.20,52 Whilst gender does not, therefore, 15 appear to be a predictor for relapse, factors which have been found to be associated 16 with failed quit attempts or resumption post-discharge include: low-confidence in 17 quitting; fewer prior attempts to quit; low household income; having other smokers in 18 the household; high nicotine dependence; low self-efficacy; severity of withdrawal 19 symptoms; lower education level; ethnicity; behavioural and psychosocial 20 factors.14,16,19,53-55 People who are depressed or suffer from anxiety or psychiatric 21 disorders are known to be particularly vulnerable to relapse.14,50 Women have been 22 shown to find smoking cessation more difficult at certain stages of the menstrual cycle; 23 but in light of the older age of onset of CHD in women,6 it is unlikely to be a factor in 24 smoking relapse amongst this generally post-menopausal cohort. 25   11 | P a g e   
 The relationships between clinical factors such as type of CHD diagnosis, disease 1 severity, extent of coronary intervention and rate of relapse are interesting, though not 2 fully understood. Whilst those relationships were outside the specific aims of this 3 systematic review, we found that the study in which all patients underwent CABG had 4 the highest cessation rate.32 A recent randomised controlled trial with 5-year follow up 5 reported that coronary revascularization reduced the number of smokers by half, which 6 led the investigators to think about the effectiveness of smoking cessation advice at the 7 time of revascularization.56 Whilst others have also found high rates of abstinence for 8 CABG patients compared to those admitted for MI,43 one study noted that previous 9 CABG appeared to be a paradoxically positive predictor of relapse.50 Perez et al.50 10 hypothesised that undergoing CABG might lead patients to mistakenly think their 11 disease was cured and be more complacent about smoking cessation. Another study 12 found that higher cessation rates in CABG patients one month post-procedure were no 13 longer apparent at 12 months, which caused the investigators to wonder whether 14 longer hospitalisation due to CABG was an influencing factor for short-term 15 abstinence.57 It is interesting to note that the two studies included in our review in 16 which the rate of relapse was significantly higher in females than males were those 17 which only included patients who had received PCI with stent or underwent cardiac 18 surgery,23,24 although rates of relapse did not differ significantly by gender in the study 19 limited to CABG patients.32  Blum et al.23 interpreted the lower rate of cessation in 20 females as a weakness of the intervention, suggesting that in future it should be better 21 targeted towards females. 22  Hospitalisation with ACS has been identified as a teachable moment for smoking 23 cessation, but nevertheless – as confirmed in this review - rates of relapse are often 24 high.57 Patients may feel greater motivation to quit following a health scare and use the 25   12 | P a g e   
period of enforced abstinence in hospital to kick-start their cessation attempt.14,58 1 However, the duration of hospitalisation for MI can be quite short and lack of time may 2 impede the delivery of smoking cessation support.5 A longer stay in hospital or longer 3 recovery period (for example related to more severe, multi-vessel or major artery 4 disease, coronary interventions or CABG) has been shown to positively influence 5 smoking cessation, possibly because it gives clinicians more time to try to motivate 6 patients and their relatives to quit smoking.28,32,49,57  7  Half of the patients in our study were able to quit smoking spontaneously but the 8 other half (47%) continued to smoke post-diagnosis or hospitalisation. This is 9 consistent with other studies which have noted 30%-60% smoking relapse rates in CHD 10 populations.14,49,50 In our review, although rates of persistent smoking/relapse were 11 lower in studies which had relatively short (3 months) follow-up periods, length of 12 follow-up did not affect the direction of the effect in meta-analysis of relapse by gender, 13 which was consistently similar in females and males. The weeks immediately following 14 hospital discharge are often when patients are most susceptible to relapse, as they settle 15 back into their normal routine and life-style.25,53 The follow-up periods in the included 16 studies varied from three months to thirteen years, and we note that both studies which 17 found a higher rate of relapse amongst females than males had relatively long follow-up 18 periods (>1 year).23,24 In relation to the length of follow-up, in their systematic review 19 and meta-analysis of relapse after one year of abstinence, Hughes et al.59 concluded that 20 a non-significant amount of relapse occurs after a year but did not report on this by 21 gender.  22  High rates of persistent smoking/relapse post-diagnosis or hospitalisation for 23 CHD highlight the importance of interventions which support patients and improve 24 smoking cessation. Although, as we have shown, the rate of persistent smoking/relapse 25   13 | P a g e   
is similar in females and males, gender differences in the experience of smoking and 1 relapse remain important issues for an effective intervention design. For example, it has 2 been demonstrated that females attempting to quit experience a higher impact of 3 depression, more severe withdrawal symptoms, more fear of weight gain and have a 4 greater reliance on social supports than males, prompting the World Health 5 Organization Framework Convention on Tobacco Control to recommend a gendered 6 perspective in prevention programs.17  However, evidence to date indicates that, 7 although female specific programs do help women to stop smoking, such programs 8 produce similar abstinence rates to non-gender-specific programs.15  Attendance at 9 cardiac rehabilitation has been shown to be effective in improving smoking cessation, 10 nevertheless substantial proportion of attendees are known to relapse within a few 11 weeks.25,53  Evidence also suggests that intensive, sustained interventions, involving 12 behavioural modification counselling along with pharmacotherapy, nursing 13 interventions and interventions addressing tempting situations, are the most 14 effective.60-63 Multifactorial lifestyle interventions to improve modifiable risk factors, 15 including smoking cessation, diet and physical activity, have also been shown to reduce 16 mortality and morbidity in CHD patients.64 Few studies in in our review involved a 17 specific smoking intervention, but amongst those that did, three noted improved 18 smoking cessation in the intervention group,22,23,26 whilst the fourth found no additional 19 benefit of bupropion over and above intensive nurse counselling.33 Many tools to assist 20 in smoking cessation support have been validated for use by health care professionals, 21 including motivational interviewing and use of the 5 A’s (Ask, Advise, Assess, Assist, 22 Arrange) when addressing patient’s tobacco use.17 Motivational interviewing has been 23 shown to improve rates of smoking cessation and nurse-led motivational interviewing 24 has been used successfully in patients.65 The delivery of smoking cessation advice for 25   14 | P a g e   
patients post ACS is also recognised as being the responsibility of physicians in general 1 practices.66 In light of the fact that smoking cessation is so important, and because 2 admission to hospital provides patients with an impetus to quit smoking, more 3 consistent and sustained interventions are required in order to capitalise on this 4 opportunity to provide cessation support to both female and male smokers.62,63,67  5 
Limitations 6 There was some heterogeneity between studies in terms of sample populations, follow-7 up and interventions. However, we addressed this by using the random effects model 8 and conducting sensitivity analyses to ensure that variances in study design did not 9 change our overall findings. Since smoking prevalence was not the main objective of the 10 review, we included a number of studies where all participants were smokers and 11 baseline. This means that our prevalence of 7% female smokers in the aggregated 12 sample is likely to be an overestimate. We addressed this issue by analysing prevalence 13 in females vs. males in the eight studies which also included non-smokers. 14 
 15 
CONCLUSION 16 Female smokers with CHD were relatively uncommon in the included study 17 populations. However, the rate of persistent smoking/relapse was high in both female 18 and male smokers following a diagnosis or hospitalisation for CHD. Therefore, similar, 19 sustained smoking cessation efforts are warranted for both genders. 20 
 21 
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Table 1: Summary of study characteristics  
Source Country Design Study population Sample 
size 
n 
Mean age 
of the 
sample 
(years) 
Smokers at 
baseline    
n (%c) 
Definition of 
persistent/relapsed 
and follow up period 
Persistent 
/relapsed 
smokers 
  n (%d) Kinjo, K. (2005)29 Japan Prospective cohort Patients hospitalised for MI and survived >3 months after discharge 2579 (21.6% women) 64 1424 (55.2) Self-reported smoking at 3 months post-discharge 368 (25.8) Rallidis, L. S. (2005)34 Greece Prospective cohort Patients aged <75 with a history of MI >6 months ago and attending a cardiology clinic 
1011 (16.8% women) 60 667  (66.0) Self-reported smoking at follow up 2-3 years post-event 329 (49.3) Scholte op Reimer, W. (2006)35 15 European countries a Cross sectional Patients aged <71 with first MI or myocardial ischemia or first CABG or PCTA >6 months ago 
5551 (23.7% women) N/A 2244 (40.4) Self-reported smoking at follow up median 1.5 years post-event 1172 (52.2) Dawood, N. (2008) 26 USA Prospective cohort Patients hospitalized for MI who were self-reported smokers on admission 
639 (32.9% women) 54 639 (100) Self-reported smoking, even a puff, in the past 30 days at follow up 6 months post-discharge. 
342 (53.5) 
Ota, A. (2008)31  Japan Prospective cohort Patients hospitalised with a diagnosis of ACS or stable angina and a declaration of daily smoking 
90 (10% women) 63 90 (100) Lack of self-reported abstinence 3 months post-discharge 32 (35.6) 
Pietrobon, R.C. (2010)32  
Brazil  Prospective cohort Patients undergoing CABG for CHD 203 (34% women) 62 146 (71.9) Self-reported smoking at 60 and 90 days post CABG 10 (6.8) Vogiatzis, I. (2010) 36 Greece Prospective cohort Patients aged <76 and active smokers at the time of admission to CCU with ACS 
420 (23.8% women) 60 420 (100) Self-reported smoking at one year post-discharge 258 (61.4) Colivicchi, F. (2011) 25 Italy Prospective cohort Patients admitted for ACS who were current active smokers and declared 1294 (21.3% women) 60 1294 (100) Self-reported resumed regular smoking during 12 month 813 (62.8)   26 | P a g e   
they were motivated to permanently quit smoking. follow up post-event Gerber, Y. (2011)28 Israel Prospective cohort Patients hospitalised with first MI who were smoking at the time of admission 
768 (12.7% women) 51 768 (100) Self-reported persistent smoking at one or more of follow ups over a period of 13 years post-event 
422 (54.9) 
Planer, D. (2001)33 Israel RCT Patients hospitalised for ACS weighing more than 45kg and smoking   >10 cigarettes/day, who exhibited intention to quit smoking 
149 (20.1% women) 52 149 (100) Self-reported continuous abstinence at one year post-discharge 
Not stated 
Chen, T. (2012)24 China Prospective cohort Patients who underwent successful PCI with at least one stent 17624 (21.4% women) 58 8489 (48.2) Self-reported smoking at any time during the minimum 1 year follow up period post PCI procedure 
4049 (47.7) 
Newsom, J.T. (2012)30 Canada Prospective cohort Population sample reporting being newly diagnosed with heart disease (i.e. heart attack, CHD, angina, congestive heart failure, or other heart problems) 
1996 (44.1% women) 56 490 (24.5) Self-reported smokers 0 to 2 years post-diagnosis 299 (61.0) 
Blum, M.R. (2013)23 Switzerland Prospective cohort Patients with CABG, ACS with PCI, CHF, or cardiac valve surgery who participated in the cardiac rehabilitation program 
201 (17.9% women) 56 90 (44.8) Self-reported smoking within the last 12 months at follow-up average 1.4 years post-event 
34 (37.8) 
de Boer, S. P. M. (2013)27 The Netherlands Prospective cohort Patients aged ≥18 undergoing PCI and survived to 1 year 856 (24.4% women) 56 497 (58.1) Self-reported smokers before PCI and at 1 year post PCI 287 (57.7) Berndt, N. (2014)22 The Netherlands RCT Patients aged ≥18  admitted to the cardiac ward for less than 96 hours for ACS, stable angina, or other forms of chronic and acute heart 
625 (26.9% women) 56 625 (100) Self-reported smoked >5 cigarettes in the 90 days prior to the 6 month post-event follow up 
not stated 
  27 | P a g e   
diseases who were current or recently quit smokers (<4 weeks) Prugger, C (2014)37 22 European countries b Cross sectional Patients aged 18-79 with first or recurrent diagnosis or treatment for CHD (MI or myocardial ischemia or  CABG or PCTA) >6 months ago who were smokers at the time of hospital admission 
2585 (16.2% women) 55 2585 (100) Pre-contemplation, Contemplation or Preparation stage of change i.e. self- reported not thinking of quitting, thinking of quitting (but not attempted), thinking of quitting and at least one failed quit attempt in the last year. 
1305 (50.5) 
Abbreviations: MI myocardial infarction; ACS acute coronary syndrome (including MI and unstable angina); PCI Percutaneous coronary intervention; PCTA percutaneous transluminal coronary angioplasty; CABG coronary artery bypass graft; CHF chronic heart failure; CCU coronary care unit; CHD coronary heart disease 
a EUROASPIRE II: Czech Republic, Finland, Germany, Hungary, Italy, the Netherlands, Slovenia, Spain, Belgium, France, Greece, Ireland, Poland, Sweden, and the United Kingdom. b EUROASPIRE III: Czech Republic, Finland, France, Germany, Hungary, Italy, the Netherlands, Slovenia, Spain, Belgium, Greece, Ireland, Poland, the United Kingdom, Bulgaria, Croatia, Cyprus, Latvia, Lithuania, Romania, Russian Federation and Turkey. c Percentage of total sample smoking at baseline. d Percentage of baseline smokers still smoking at follow up. 
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Table 2: Prevalence of smoking at baseline and smoking relapse by gender 
Source Smokers at baseline Persistent/relapsed smokers at follow up 
 Males 
n (%a) 
Females 
n (%b) p-value 
Males 
n (%c) 
Females 
n (%c) p-value Kinjo, K. (2005)  1276 (63.1) 148 (26.6) < 0.0001 328 (25.7) 40 (27.0) 0.73 Rallidis, L. S. (2005)  607 (72.2) 60 (35.3) < 0.0001 303 (49.9) 26 (43.3) 0.33 Scholte op Reimer, W. (2006)  1829 (43.2) 415 (31.5) < 0.0001 941 (51.4) 231 (55.7) 0.12 Dawood, N. (2008)  429 (100) 210 (100) n/a 228 (53.1) 114 (54.3) 0.79 Ota, A. (2008)  81 (100) 9 (100) n/a 29 (35.8) 3 (33.3) 0.88 Pietrobon, R.C. (2010)  107 (79.9) 39 (56.5) 0.0006 7 (6.5) 3 (7.7) 0.81 Vogiatzis, I. (2010)  320 (100) 100 (100) n/a 196 (61.3) 62 (62.0) 0.89 Colivicchi, F. (2011)  1018 (100) 276 (100) n/a 610 (59.9) 203 (73.6) < 0.0001 Gerber, Y. (2011)  667 (100) 101 (100) n/a 373 (55.9) 49 (48.5) 0.16d Planer, D. (2001)  119 (100) 30 (100) n/a not stated not stated 0.91d Chen, T. (2012)  8185 (59.1) 304 (8.1) < 0.0001 3888 (47.5) 161 (53) 0.06 Newsom, J.T. (2012)  286 (25.6) 204 (23.2) 0.21 171 (59.8) 128 (62.7) 0.51 Blum, M.R. (2013)  78 (47.3) 12 (33.3) 0.13 26 (33.3) 8 (66.7) 0.04 de Boer, S. P. M. (2013)  428 (66.2) 69 (33.0) < 0.0001 251 (58.6) 36 (52.2) 0.31 Berndt, N. (2014)  457 (100) 168 (100) n/a not stated not stated 0.43 Prugger, C (2014)  2166 (100) 419 (100) n/a 1096 (50.6) 209 (49.9) 0.79 a Percentage of males in sample who were smokers at baseline; 100% where all study participants were smokers, therefore p-value not applicable. b Percentage of females in sample who were smokers at baseline; 100% where all study participants were smokers, therefore p-value not applicable. c Percentage of smokers at baseline who were persistent/relapsed smokers at follow up. d p-value for these two studies extracted from results of multivariate analysis presented in article 
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Figure 1: Selection of studies 
 
a EUROASPIRE II: 15 European countries (Czech Republic, Finland, Germany, Hungary, Italy, the Netherlands, Slovenia, Spain, Belgium, France, Greece, Ireland, Poland, Sweden, and the United Kingdom). 
b EUROASPIRE III: 22 European countries (Czech Republic, Finland, France, Germany, Hungary, Italy, the Netherlands, Slovenia, Spain, Belgium, Greece, Ireland, Poland, the United Kingdom, Bulgaria, Croatia, Cyprus, Latvia, Lithuania, Romania, Russian Federation and Turkey) 
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Figure 2: Sample profile: Gender and smoking status at baseline 
 Percentages based on total sample size for the study. 
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Figure 3: Forest plot showing gender differences for persistent smoking or relapse post CHD diagnosis or hospitalisation 
 Abbreviations: OR Odds ratio; CI confidence interval.  
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